Humans are frequently exposed to seasonal influenza viruses like H1N1, H3N2 and influenza B viruses. However, infections with avian influenza viruses like H5N1 or H7N9 are rare. So far it is unclear how the human immune system reacts to exposure to these viruses, specifically in the context of pre-existing immunity to seasonal influenza virus strains. Preliminary data has shown that in these rare cases antibodies to epitopes that are conserved between human seasonal and avian influenza viruses are boosted. In this collaborative effort between the Xu laboratory (Fudan University, Shanghai, China) and the Krammer laboratory (Icahn School of Medicine at Mount Sinai, New York, USA) we propose to investigate the human antibody response after natural infection with avian influenza viruses. Antibody responses will be characterized at three levels. Initially we will assess the reactivity and functionality of polyclonal serum responses of humans naturally infected with H7N9 viruses. Then, on an epidemiologic level, we will assess the cross-reactivity of 'at risk' cohorts (wet market vendors, bird handlers, farmers etc.) to get insights into the prevalence of exposure to avian influenza viruses. Finally, we will zoom in to characterize the epitope usage of monoclonal antibodies induced after infection with avian influenza viruses. The data obtained from this study will guide the design of novel broadly protective and pandemic influenza virus vaccines and will significantly enhance our pandemic preparedness.

Public Health Relevance

Infection with avian influenza virus is an unusual challenge for the human immune system and the antibody response to these rare infections is poorly understood. Here we will analyze the polyclonal and monoclonal antibodies induced by natural infection with avian influenza viruses in humans. The obtained data will guide future vaccine design and will enhance pandemic preparedness.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Lane, Mary Chelsea
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Icahn School of Medicine at Mount Sinai
Schools of Medicine
New York
United States
Zip Code
Henry, Carole; Palm, Anna-Karin E; Krammer, Florian et al. (2018) From Original Antigenic Sin to the Universal Influenza Virus Vaccine. Trends Immunol 39:70-79
Stadlbauer, Daniel; Amanat, Fatima; Strohmeier, Shirin et al. (2018) Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model. Emerg Microbes Infect 7:110
Meade, Philip; Latorre-Margalef, Neus; Stallknecht, David E et al. (2017) Development of an influenza virus protein microarray to measure the humoral response to influenza virus infection in mallards. Emerg Microbes Infect 6:e110
Liu, Lu; Nachbagauer, Raffael; Zhu, Lingyan et al. (2017) Induction of Broadly Cross-Reactive Stalk-Specific Antibody Responses to Influenza Group 1 and Group 2 Hemagglutinins by Natural H7N9 Virus Infection in Humans. J Infect Dis 215:518-528
Stadlbauer, Daniel; Nachbagauer, Raffael; Meade, Philip et al. (2017) Universal influenza virus vaccines: what can we learn from the human immune response following exposure to H7 subtype viruses? Front Med 11:471-479
Stadlbauer, Daniel; Rajabhathor, Arvind; Amanat, Fatima et al. (2017) Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans. mSphere 2: